Ontology highlight
ABSTRACT:
SUBMITTER: Zhou TY
PROVIDER: S-EPMC4967870 | biostudies-literature | 2016 Aug
REPOSITORIES: biostudies-literature
Zhou Tian-Yi TY Zhuang Lin-Han LH Hu Yan Y Zhou Yu-Lu YL Lin Wen-Kai WK Wang Dan-Dan DD Wan Zi-Qian ZQ Chang Lin-Lin LL Chen Ying Y Ying Mei-Dan MD Chen Zi-Bo ZB Ye Song S Lou Jian-Shu JS He Qiao-Jun QJ Zhu Hong H Yang Bo B
Scientific reports 20160801
Sorafenib is a multikinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma (HCC), but it has shown modest to low response rates. The characteristic tumour hypoxia of advanced HCC maybe a major factor underlying hypoxia-mediated treatment failure. Thus, it is urgent to elucidate the mechanisms of hypoxia-mediated sorafenib resistance in HCC. In this study, we found that hypoxia induced the nuclear translocation of Yes associate-Protein (YAP) and the subsequent trans ...[more]